Anemia In Elderly Market Report 2026

Anemia In Elderly Market Overview

• Anemia In Elderly market size has reached to $2.99 billion in 2025 • Expected to grow to $4.59 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Elderly Population Drives Growth of Anemia in Elderly Market • Market Trend: New Personalized Iron Injection Enhances Treatment For Iron Deficiency Anemia • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anemia In Elderly Market?

Anemia in the elderly refers to a condition characterized by a reduction in the number of red blood cells (RBCs) or hemoglobin levels below the normal range, leading to diminished oxygen-carrying capacity of the blood in older adults (commonly defined as individuals aged 65 years and older). It is often caused by nutritional deficiencies, chronic diseases, or age-related changes in the body. The main type of products in anemia in elderly are tablets, and injectable. Tablets are solid, oral medications commonly used to treat anemia in older adults. The different treatments are iron supplements, erythropoietin or erythrocyte-stimulating agents, vitamin b12 supplements, and folic acid supplements. The route of administration differs as oral, and parenteral and is used by end users such as hospital pharmacy, online pharmacy, and retail pharmacy.

What Is The Anemia In Elderly Market Growth Forecast?

The anemia in elderly market size is expected to see strong growth in the next few years. It will grow to $4.59 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growing demand for personalized anemia treatment, increasing adoption of long-acting injectables, rising focus on geriatric healthcare, expansion of outpatient anemia management, improved diagnostic screening in elderly care. Major trends in the forecast period include increasing adoption of combination therapy approaches, rising use of injectable iron treatments, growing focus on early diagnosis in elderly populations, expansion of home-based treatment options, enhanced emphasis on managing chronic disease-related anemia.

Global Anemia In Elderly Market Segmentation

1) By Product Type: Tablets, Injectable 2) By Treatment: Iron Supplements, Erythropoietin Or Erythrocyte-Stimulating Agents, Vitamin B12 Supplements, Folic Acid Supplements 3) By Route Of Administration: Oral, Parenteral 4) By End User: Hospital pharmacy, Online Pharmacy, Retail pharmacy Subsegments: 1) By Tablets: Iron Supplements, Vitamin B12 Supplements, Folic Acid Tablets, Erythropoiesis-Stimulating Agents (ESAs) Tablets 2) By Injectable: Iron Injections, Vitamin B12 Injections, Erythropoiesis-Stimulating Agents (ESAs) Injections, Folic Acid Injections

What Is The Driver Of The Anemia In Elderly Market?

The growing elderly population is expected to propel the growth of the anemia in the elderly market going forward. The elderly population is the increasing number and proportion of people aged 65 and older within a given society or globally. The growth of the elderly population is due to factors including increased life expectancy, declining birth rates, and aging of large cohorts. The growing elderly population increases the prevalence of age-related and chronic conditions, which are significant causes of anemia in older adults. This drives the demand for diagnosis, management, and treatment of anemia, fueling market growth. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based Nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. Therefore, the growing elderly population is driving the growth of the anemia in elderly industry.

Key Players In The Global Anemia In Elderly Market

Major companies operating in the anemia in elderly market are Johnson & Johnson, Roche Holding AG, Merck & Co Inc, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Japan Tobacco Inc, Fresenius Medical Care AG, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, CSL Limted, Daiichi Sankyo Company Limited, Amag Pharmaceuticals, Akebia Therapeutics Inc, Pharmacosmos A/S, Rockwell Medical Inc, Bioage Labs Inc, Shield Therapeutics Plc, MegaPro Biomedical Co Ltd

Global Anemia In Elderly Market Trends and Insights

Major companies operating in the anemia in the elderly market are focusing on technological advancements, such as personalized therapies, to streamline treatment processes, improve patient outcomes, reduce side effects, and enhance overall healthcare efficiency. Customized therapies are medical treatments based on each patient's individual characteristics. For instance, in March 2024, Cadila Pharmaceuticals, an Indian-based pharmaceutical company, announced the launch of Redshot FCM, a novel iron injection designed to treat iron deficiency anemia for patients who experience oral iron intolerance. It is an intravenous iron preparation that delivers adequate amounts of iron and boosts an exemplary safety profile. The injection features an advanced Ferric Carboxymaltose formulation that improves iron delivery and absorption. Redshot FCM demonstrates a dedication to improving healthcare by developing personalized therapies that account for individual patient profiles, leading to better treatment outcomes for iron deficiency anemia.

What Are Latest Mergers And Acquisitions In The Anemia In Elderly Market?

In February 2025, AstraZeneca, a UK-based biopharmaceutical company, acquired FibroGen, Inc. for $160 million. Through this acquisition, AstraZeneca aims to strengthen its presence in the Chinese anemia therapeutics market by securing full rights to roxadustat, including its manufacturing, development, and commercialization. FibroGen Inc. is a US-based biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia.

Regional Outlook

North America was the largest region in the anemia in elderly market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anemia In Elderly Market?

The anemia in elderly market consists of revenues earned by entities by providing services such as diagnostic testing, medical consultations and treatment plans, and administration of iron infusions or blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The anemia in elderly market also includes sales of iron supplements, vitamin B12, folic acid supplements, and diagnostic equipment such as hemoglobin meters and blood test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anemia In Elderly Market Report 2026?

The anemia in elderly market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anemia in elderly industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.